ELAVL1 and breast cancer: This overexpression of NCL is mediated by the elevated expression of HuR and the downregulation of miR-194 and miR-206, which competitively bind to NCL 3′UTR, as evidenced in MCF-7 and MDA-231 cells (breast cancer cells) [64].